Kent BD. What we do and do not know about managing respiratory disease in pregnancy.
Breathe (Sheff) 2022;
18:220161. [PMID:
36342868 PMCID:
PMC9584564 DOI:
10.1183/20734735.0161-2022]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 06/22/2022] [Indexed: 11/23/2022] Open
Abstract
Prior to the twentieth century, pregnancy and childbirth were highly risky endeavours for any woman in even the most advanced societies. As recently as 1900, maternal mortality in the UK ran at close to five deaths per 1000 births, and was even higher in the USA [1]. Such a death toll would be inconceivable in the developed world now, and the transformation of societal expectations around childbirth, from an event of fear and great hazard to a joyous bonding experience, may represent one of the great achievements of modern healthcare.
Respiratory disorders are common in pregnant women, but their exclusion from clinical trials makes decisions around pharmacotherapy challenging. Developing programmes designed to improve evidence in pregnancy should be a priority for respiratory research.https://bit.ly/3n6aX42
Collapse